Bavituximab

立即咨询

Bavituximab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

648904-28-3

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

Anti-Human Phosphatidylserine Recombinant Antibody

产品介绍

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) 是一种磷脂酰丝氨酸 (PS) 靶向的单克隆抗体，能够作用肿瘤血管系统和重新激活抗肿瘤免疫来抑制肿瘤生长。Bavituximab 联合Paclitaxel (HY-B0015) 和 Carboplatin (HY-17393)，对非小细胞肺癌的抑制有加强效果。

生物活性

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plusPaclitaxel(HY-B0015) andCarboplatin(HY-17393), have enhanced inhibition on non-small-cell lungcancer^[1].

IC₅₀& Target

Phosphatidylserine (PS)^[1]

体外研究
(In Vitro)

Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)^[1].
Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction^[1].
Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells^[2].

体内研究
(In Vivo)

Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo^[2].

Animal Model:	Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors^[2]
Dosage:	100 μg/mouse (Bavituximab/β2GP1)
Administration:	Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)
Result:	Traced phosphatidylserine exposure in vivo in mice with tumors.

分子量

145.3 (kDa)

CAS 号

648904-28-3

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.